Methotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis

P.J. Mroczkowski¹, M.E. Weinblatt², J.M. Kremer³

¹Patrick J. Mroczkowski, MD, Assistant Professor of Medicine, Division of Rheumatology, Albany Medical College, Albany, New York; ²Michael E. Weinblatt, MD, Rheumatology and Immunology, Brigham & Womens Hospital, Boston, Massachusetts; ³Joel M. Kremer, MD, Professor of Medicine, Head, Division of Rheumatology, Albany Medical College, Albany, New York, USA.

ABSTRACT
An open-label, one-year study was conducted to evaluate the safety and clinical response to leflunomide and methotrexate combination therapy for rheumatoid arthritis. Study results revealed tolerable safety, no significant pharmacokinetic interactions between methotrexate and leflunomide, and suggested improved clinical reponse with combination therapy.

Key words
Rheumatoid arthritis, methotrexate, leflunomide, combination therapy.

Please address correspondence to: Patrick J. Mroczkowski, MD, Division of Rheumatology, A-100, Albany Medical College, 47 New Scotland Avenue, Albany, New York 12208-3479, USA.

Clin Exp Rheumatol 1999; 17 (Suppl. 18): S66 - S68.
© Copyright Clinical and Experimental Rheumatology 1999.